Heterocyclic Compounds

Matches 451 - 500 out of 30,734	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >

Document	Document Title
WO/2023/124205A1	ORGANIC COMPOUNDS, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS The present application provides organic compounds, an organic electroluminescent device, and an electronic apparatus. The structure of the organic compounds is shown as formula 1, the organic compounds being used in an organic electrolu...
WO/2023/129963A1	ANTIMICROBIAL COMPOUNDS AND METHODS The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-nega...
WO/2023/127805A1	ARYL TETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, PESTICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME In the production of crops in agriculture, horticulture, and the like, the occurrence of damage by pests and the like has been still a major issue, and therefore the development of new agricultural/horticultural pesticides has been deman...
WO/2023/127853A1	COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION Provided is a compound represented by formula (1) or a pharmaceutically acceptable salt thereof (in formula (1), Ar is formula (Ar1) or (Ar2), and in these formulas, R1 and R2 each independently denote an alkyl, a haloalkyl, or a halogen...
WO/2023/125275A1	SALT OF AMINOPYRIMIDINE COMPOUND AND USE THEREOF Provided are a salt of an aminopyrimidine compound and a use thereof. Specifically, provided are a salt of (S)-2-(1-((6-amino-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyrimidi n-4-yl)amino)ethyl)-5-(3-hydroxyprop-1-yn-1-yl)-3-phenylquin azolin-4...
WO/2023/116761A1	PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE A pyrimidine heterocyclic compound, a preparation method therefor and a use thereof in medicine. Specifically, a pyrimidine heterocyclic compound having a structure as shown in formula (A) or a pharmaceutically acceptable salt thereof, t...
WO/2023/122320A1	POLYPODAL SEROTONERGIC COMPOUNDS AND PRODRUGS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS Monopodal and polypodal serotonergic drugs, including prodrugs of serotonin receptor agonists and antagonists.
WO/2023/122778A1	PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defin...
WO/2023/122615A1	IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF The present disclosure relates generally to compounds of formula (I) that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use o...
WO/2023/118521A1	DIHYDRO-OXAZOL DERIVATIVE COMPOUNDS The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of th...
WO/2023/120696A1	1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE The present invention provides a compound that exhibits an anticancer effect based on Checkpoint Kinase 1 (CHK1) inhibition. It is discovered that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof has a ...
WO/2023/116920A1	PENTA- FUSED HEXA-HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE A penta- fused hexa-heterocyclic compound, a preparation method, a pharmaceutical composition, and the use. The penta- fused hexa-heterocyclic compound is a compound represented by formula (II) or (III). The compound has an inhibition or...
WO/2023/118875A1	PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS The invention relates to a compound of formula (I) which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3 -yl)methyl)phthalazin-1(2H)- one; or a salt and/or solvate thereof; and to its use in treating or preventing an infl...
WO/2023/121992A1	CYCLOPROPYL COMPOUNDS The invention provides new heterocyclic compounds having the general formula (I'), or a solvate or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, compositions including the co...
WO/2023/116866A1	FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF A five- and six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory...
WO/2023/118253A1	CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are cyclohexane acid derivatives, methods of preparing such comp...
WO/2023/121238A1	SUBSTITUTED HETEROCYCLIC DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME The present invention relates to a substituted heterocyclic derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a stereoisomer thereof, a hydrate thereof, or a pharmace...
WO/2023/118560A1	CRYSTALLISATION PROCESS FOR RIVAROXABAN This invention describes a process for the preparation of rivaroxaban modification I comprising: (i) recrystallising rivaroxaban in acetic acid in the presence of a reducing agent; and (ii) collecting the resultant rivaroxaban modificati...
WO/2023/118434A1	PESTICIDALLY ACTIVE AMIDE COMPOUNDS The present invention relates to novel pesticidally active amide compounds and in particular heteroaromatic amide compounds, to compositions comprising those compounds, and to their use in agriculture, for example in controlling insect p...
WO/2023/116882A1	PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR Provided are a pharmaceutically acceptable salt and a crystalline form of a GLP-1 receptor agonist and a preparation method therefor. Specifically, provided are a pharmaceutically acceptable salt and a crystalline form of a compound 2-((...
WO/2023/122276A1	METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...
WO/2023/115394A1	DIARYLAMINE COMPOUND AND USE THEREOF, LIGHT EXTRACTION MATERIAL, ELECTROLUMINESCENT DEVICE, AND DISPLAY DEVICE A diarylamine compound and use thereof, a light extraction material, an electroluminescent device, and a display device. The structural general formula of the diarylamine compound is formula (I).
WO/2023/120452A1	SREBP-1 INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR TREATING HYPERTRIGLYCERIDEMIA This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by fo...
WO/2023/122267A2	SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.
WO/2023/122152A1	KCNT1 INHIBITORS AND METHODS OF USE The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-func...
WO/2023/112856A1	FUSED HETEROCYCLIC DERIVATIVE AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT The present invention provides a novel fused heterocyclic derivative or an agriculturally acceptable salt thereof, and an herbicide containing the same as an active ingredient.　Provided are a fused heterocyclic derivative represented b...
WO/2023/113575A1	COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to a compound of Formula 1 and an organic light-emitting device comprising same.
WO/2023/114198A2	METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof. The methods involve subjecting an intermediate in the synthesis of a complement factor D inhibitor to a t-butyl ester ...
WO/2023/110473A1	HETEROCYCLIC COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
WO/2023/114733A1	KRAS MODULATORS AND USES THEREOF Provided herein are KRAS modulating compounds, such as compounds of Formula (I) and various Sub Formulas or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modul...
WO/2023/114061A1	CRYSTALLINE FORMS OF A RIPK1 INHIBITOR The present invention provides a crystalline compound of the formula : wherein the crystalline compound is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and psoriasis.
WO/2023/109004A1	NAPHTHYLUREA-PIPERAZINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF A naphthylurea-piperazine compound, a preparation method therefor and a use thereof. The compound can significantly inhibit the activation of JAKs/STATs signaling at a low dose. The results of cell proliferation experiments, western blot...
WO/2023/109745A1	SMALL-MOLECULE PROBE FOR IMAGING OF α-SYNUCLEIN AGGREGATE Provided are a compound of general formula I capable of specifically binding to an α-synuclein aggregate, a radiolabeled compound thereof, a preparation method therefor, and a use thereof. The compound can be used as a small-molecule pr...
WO/2023/113576A1	COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
WO/2023/110871A1	MICROBIOCIDAL PYRAZOLE DERIVATIVES A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
WO/2023/110710A1	METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS & COMPOUNDS THEREFOR A method for combating and controlling diamide-resistant insects to(i) reduce damage on a plant, which comprises applying to the insect, to a locus of the insect, or to a plant susceptible to attack by the insect, an effective amount of ...
WO/2023/113577A1	COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to compounds of chemical formula 1 and chemical formula 2 and an organic light-emitting device comprising same.
WO/2023/110138A1	INHIBITORS OF TRANSGLUTAMINASES The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
WO/2023/114365A1	METHODS AND COMPOSITIONS FOR TARGETING PD-L1 The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
WO/2023/111181A1	SMALL MOLECULE MODULATORS OF IL-17 The present invention relates to a compound according to formula (I), and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical composition...
WO/2023/114428A1	HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE The disclosure provides heterocycle derivatives of Formula (I) for the inhibition of the oligosaccharyltransferase complex and the treatment of disease.
WO/2023/107145A1	COMPOSITIONS AND METHODS FOR TREATING CANCER The present disclosure relates generally to methods for treating cancer, in particular hematologic cancers, with an N-(1H-imidazol-2-yl)benzamide compound of a salt thereof, optionally in combination with a PARP inhibitor or a BTK inhibi...
WO/2023/107979A1	TREATMENT OF CANCER WITH AN FGFR KINASE INHIBITOR Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise an FGFR kinase inhibitor. Some embodiments comprise combination therapy featuring the FGFR kinase inhibitor with at least one oncology...
WO/2023/104170A1	COMPOUNDS FOR TREATING POLYQ-RELATED NEURODEGENERATIVE DISORDERS One embodiment of the disclosure is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) can be used to treat polyQ-related neurode...
WO/2023/107722A1	COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS This disclosure provides compounds of formula (I) and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating ...
WO/2023/107660A1	SOLID STATE FORMS OF LOTILANER AND PROCESS FOR PREPARATION THEREOF The present disclosure encompasses a solid-state form of Lotilaner, in embodiment processes for preparation thereof, and pharmaceutical compositions thereof. The present disclosure further encompasses Lotilaner salts and their solid stat...
WO/2023/104564A1	PYRAZINE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
WO/2023/107863A1	HETEROCYCLIC COMPOUNDS AS KIT KINASE INHIBITORS Described herein are compounds of Formula I that are inhibitors of wild type and oncogenic mutant c-KIT kinase and their use in the treatment of disorders such as cancers.
WO/2023/107714A2	METHODS FOR TREATING NEUROLOGICAL DISORDERS This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, di...
WO/2023/105387A1	MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF Described herein are compounds of Formula I: I and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R7, RF, t1, Y1, and Y2 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such com...

Matches 451 - 500 out of 30,734	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >